Combination of Biologic and Anti-obesity Therapies in Psoriatic Arthritis (NCT07443956) | Clinical Trial Compass
RecruitingNot Applicable
Combination of Biologic and Anti-obesity Therapies in Psoriatic Arthritis
United Kingdom45 participantsStarted 2026-03-09
Plain-language summary
This is a trial to find out how weight loss (achieved by the use of tirzepatide) or ixekizumab treatment affects the characteristics of skin, joint and fat tissues in patients with Psoriatic Arthritis, Psoriasis and obesity/overweight BMI \>=27.
Participants will be allocated either Tirzepatide, Ixekizumab or both. Samples of joint tissue, fat and skin will be taken at the start of the study and week 12. Blood and urine samples will also be taken.
The primary objective will be to assess the changes seen in the joint, fat and skin tissue samples 12 weeks after starting the medications (additional analysis will be done on the optional 36 week samples).
Secondary objectives will be
* To assess the changes seen in blood 4, 12, 36 and 52 weeks after starting the medication.
* To compare the changes seen in tissue and blood between Ixekizumab and Tirzepatide/Weight loss.
* To see how the changes seen in the tissue relate to weight loss.
Who can participate
Age range18 Years – 75 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Age \>= 18 years and \<=75 years
✓. Have a documented diagnosis of PsA for at least 6 months AND fulfil the CASPAR criteria (Defined as \>=3 points)
✓. Have active PsA defined as \>=3 swollen and \>=3 tender joints (dactylitis counts as a swollen joint).
✓. Have a BMI \>= 27 kg/m\^2
✓. Have at least one affected joint amenable to ultrasound-guided synovial biopsy (and must undergo successful synovial biopsy prior to randomisation)
✓. Have at least one psoriatic plaque amenable to biopsy (up to a maximum of 5 participants per treatment arm can be recruited without skin biopsy if no suitable lesion
✓. Capable of giving signed informed consent
✓. Willing and able to participate in the study and undergo synovial, adipose and skin (if appropriate) biopsies (under local anaesthetic) on at least 2 occasions
Exclusion criteria
✕
What they're measuring
1
Correlation of molecular changes in biopsies (skin, synovial and adipose) with weight loss
. Previous treatment with tirzepatide or any GLP-1 receptor agonist.
✕. Previous treatment with Ixekizumab.
✕. Previous treatment with BOTH secukinumab AND Bimekizumab. \[note: Previous treatment with one of EITHER secukinumab OR Bimekizumab for PsA/psoriasis is allowed PROVIDED: i) Last dose was \>6months before baseline AND ii) Therapy was not stopped due to an IL-17-related side effect OR due to complete primary lack of response.
✕. Previous treatment with rituximab.
✕. Failed \>3 classes of advanced therapies (regardless of given for PsA or psoriasis), including but not limited to:
✕. If currently receiving conventional DMARDs, or apremilast, must have been treated for at least 12 weeks prior to first biopsy visit and on a stable dose for at least 8 weeks prior to first biopsy visit.
✕. Use or oral, intra-articular, IM or IV corticosteroids 4 weeks prior to first biopsy visit or anticipated/planned prior to the week 12 biopsy visit.
✕. Topical steroids within 2 weeks of first biopsy visit (participants on topical corticosteroids at baseline willing to leave these off 2 weeks prior to biopsy will be eligible).